Computational molecular modeling in peptide design: A dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
碩士 === 高雄醫學大學 === 醫學系生物化學科碩士班 === 104 === This dissertation, studies the MDMX and MDM2 interactions with the peptide inhibitors related to the research of computer-aided drug design(CADD) by employing the molecular simulations approach. These results can help drug designers to improve their products...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | zh-TW |
Published: |
2016
|
Online Access: | http://ndltd.ncl.edu.tw/handle/49729322910841436344 |
id |
ndltd-TW-104KMC05107003 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-104KMC051070032017-08-12T04:35:42Z http://ndltd.ncl.edu.tw/handle/49729322910841436344 Computational molecular modeling in peptide design: A dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy 以分子模擬方法研究雙抑制性胜肽抑制劑針對p53-dependent癌症中MDM2與MDMX蛋白抑制模型 Yi-Ting Liu 劉奕廷 碩士 高雄醫學大學 醫學系生物化學科碩士班 104 This dissertation, studies the MDMX and MDM2 interactions with the peptide inhibitors related to the research of computer-aided drug design(CADD) by employing the molecular simulations approach. These results can help drug designers to improve their products for treating special diseases. Antibody drugs specifically recognize antigens. To date, antibody drugs have already been widely applied to treat formidable disease, such as cancer. Traditional antibodies design strategy is used to inject the mouse with the disease association antigen and mouse monoclonal antibodies (Mabs) are generated. Then the CDR regions of the Mabs are modified by molecular biology techniques. Then the best modified Mabs will be changed the scaffold to generate humanized monoclonal antibody, produce by hybridoma techniques. Thus, the traditional antibodies design strategy takes time as well as money. The peptide drugs are defined as molecules containing fewer than 50 amino acids. The advantages of peptides drugs are: (1) high potency and selectivity for disease targets; (2) potentially lower toxicity than small molecules and Low accumulation in tissues; (3) high chemical and biological diversity and (4) discoverable at peptide and or nucleic acid levels. Our results are shown in below: (1) develop a tenure can speed up simulation time and accuracy of the preferred computing strategy (2) predicitng the hot-spots residues of dual inhibitors of MDM2 and MDMX; (3) predicting the 3D models of MDMX and MDM2 with the peptide inhibitors. The results of this paper to develop a strategy calculated by adding Gaussian molecular dynamics, computational analysis by binding of MDM2 to verify and confirm this group has indeed been calculated strategy to accelerate the simulation time and preferred to maintain accuracy, and therefore this calculation method as a basis for analyzing the structure and mode dual inhibit binding MDM2 / MDMX peptides and MDM2 / MDMX between the final results of our analysis of the relationship between peptide binding and MDM2 / MDMX between the important amino acids, can as the future direction of the future development of peptide inhibitors. Yeng-Tseng Wang 王焰增 2016 學位論文 ; thesis 63 zh-TW |
collection |
NDLTD |
language |
zh-TW |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 高雄醫學大學 === 醫學系生物化學科碩士班 === 104 === This dissertation, studies the MDMX and MDM2 interactions with the peptide inhibitors related to the research of computer-aided drug design(CADD) by employing the molecular simulations approach. These results can help drug designers to improve their products for treating special diseases. Antibody drugs specifically recognize antigens. To date, antibody drugs have already been widely applied to treat formidable disease, such as cancer. Traditional antibodies design strategy is used to inject the mouse with the disease association antigen and mouse monoclonal antibodies (Mabs) are generated. Then the CDR regions of the Mabs are modified by molecular biology techniques. Then the best modified Mabs will be changed the scaffold to generate humanized monoclonal antibody, produce by hybridoma techniques. Thus, the traditional antibodies design strategy takes time as well as money. The peptide drugs are defined as molecules containing fewer than 50 amino acids. The advantages of peptides drugs are: (1) high potency and selectivity for disease targets; (2) potentially lower toxicity than small molecules and Low accumulation in tissues; (3) high chemical and biological diversity and (4) discoverable at peptide and or nucleic acid levels.
Our results are shown in below: (1) develop a tenure can speed up simulation time and accuracy of the preferred computing strategy (2) predicitng the hot-spots residues of dual inhibitors of MDM2 and MDMX; (3) predicting the 3D models of MDMX and MDM2 with the peptide inhibitors.
The results of this paper to develop a strategy calculated by adding Gaussian molecular dynamics, computational analysis by binding of MDM2 to verify and confirm this group has indeed been calculated strategy to accelerate the simulation time and preferred to maintain accuracy, and therefore this calculation method as a basis for analyzing the structure and mode dual inhibit binding MDM2 / MDMX peptides and MDM2 / MDMX between the final results of our analysis of the relationship between peptide binding and MDM2 / MDMX between the important amino acids, can as the future direction of the future development of peptide inhibitors.
|
author2 |
Yeng-Tseng Wang |
author_facet |
Yeng-Tseng Wang Yi-Ting Liu 劉奕廷 |
author |
Yi-Ting Liu 劉奕廷 |
spellingShingle |
Yi-Ting Liu 劉奕廷 Computational molecular modeling in peptide design: A dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy |
author_sort |
Yi-Ting Liu |
title |
Computational molecular modeling in peptide design: A dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy |
title_short |
Computational molecular modeling in peptide design: A dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy |
title_full |
Computational molecular modeling in peptide design: A dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy |
title_fullStr |
Computational molecular modeling in peptide design: A dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy |
title_full_unstemmed |
Computational molecular modeling in peptide design: A dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy |
title_sort |
computational molecular modeling in peptide design: a dual inhibitor of mdm2 and mdmx for p53-dependent cancer therapy |
publishDate |
2016 |
url |
http://ndltd.ncl.edu.tw/handle/49729322910841436344 |
work_keys_str_mv |
AT yitingliu computationalmolecularmodelinginpeptidedesignadualinhibitorofmdm2andmdmxforp53dependentcancertherapy AT liúyìtíng computationalmolecularmodelinginpeptidedesignadualinhibitorofmdm2andmdmxforp53dependentcancertherapy AT yitingliu yǐfēnzimónǐfāngfǎyánjiūshuāngyìzhìxìngshèngtàiyìzhìjìzhēnduìp53dependentáizhèngzhōngmdm2yǔmdmxdànbáiyìzhìmóxíng AT liúyìtíng yǐfēnzimónǐfāngfǎyánjiūshuāngyìzhìxìngshèngtàiyìzhìjìzhēnduìp53dependentáizhèngzhōngmdm2yǔmdmxdànbáiyìzhìmóxíng |
_version_ |
1718515824854040576 |